Lite Strategy, Inc. (LITS)
1.03
+0.06
(+5.96%)
USD |
NASDAQ |
Nov 06, 10:29
Lite Strategy Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.2286 |
| December 31, 2023 | 0.2022 |
| September 30, 2023 | 0.1522 |
| June 30, 2023 | 0.5169 |
| March 31, 2023 | 0.3799 |
| December 31, 2022 | 0.2764 |
| September 30, 2022 | 0.3667 |
| June 30, 2022 | 0.184 |
| March 31, 2022 | 0.1481 |
| December 31, 2021 | 0.1069 |
| September 30, 2021 | 0.2536 |
| June 30, 2021 | 0.1678 |
| March 31, 2021 | 0.1892 |
| December 31, 2020 | 0.1186 |
| September 30, 2020 | 0.1054 |
| June 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0013 |
| December 31, 2019 | 0.0039 |
| September 30, 2019 | 0.0106 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| SELLAS Life Sciences Group, Inc. | 0.0054 |
| ACADIA Pharmaceuticals, Inc. | 0.0413 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 42.69M |
| Total Liabilities (Quarterly) | 1.069M |
| Shareholders Equity (Quarterly) | 41.62M |
| Current Ratio | 5.745 |